Impact of granulocyte colony‐stimulating factor on safety of chimeric antigen receptor‐T‐cell therapy in non‐Hodgkin lymphoma

Documenti analoghi

• Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T‐cell therapy: A CIBMTR analysis
  di: Narendranath Epperla, et al.
  Pubblicazione: (2024)
• Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
  di: Joshua Mehr, et al.
  Pubblicazione: (2024)
• Chimeric antigen receptor T‐cell therapy in secondary central nervous system lymphoma: A multicenter analysis
  di: Aseel Alsouqi, et al.
  Pubblicazione: (2024)
• Hemingway, Ecology and Culture
  di: Sion Ng, Lay
  Pubblicazione: (2026)
• Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma
  di: Nobuhiko Yamauchi, et al.
  Pubblicazione: (2024)